Status:
COMPLETED
Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
Lead Sponsor:
Incyte Corporation
Conditions:
Psoriasis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.
Eligibility Criteria
Inclusion
- Subjects must have psoriatic lesions measuring protocol specific BSA
Exclusion
- Lesions solely involving the palms of the hands, the soles of the feet, the intertriginious areas, the scalp or the face
- Pustular psoriasis or erythroderma
Key Trial Info
Start Date :
August 31 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2009
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00617994
Start Date
August 31 2007
End Date
May 31 2009
Last Update
February 8 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Fridley, Minnesota, United States, 55432
2
Rochester, New York, United States, 14623
3
Austin, Texas, United States, 78759
4
College Station, Texas, United States, 77840